BioMaxima Gelecekteki Büyüme

Future kriter kontrolleri 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for BioMaxima.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Medical Equipment kazanç büyümesi19.0%
Gelir büyüme oranın/a
Gelecekteki özkaynak getirisin/a
Analist kapsamı

None

Son güncellemen/a

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

BioMaxima (WSE:BMX) Is Carrying A Fair Bit Of Debt

Aug 22
BioMaxima (WSE:BMX) Is Carrying A Fair Bit Of Debt

BioMaxima S.A.'s (WSE:BMX) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Jun 08
BioMaxima S.A.'s (WSE:BMX) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

BioMaxima S.A.'s (WSE:BMX) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Apr 21
BioMaxima S.A.'s (WSE:BMX) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Returns On Capital Are Showing Encouraging Signs At BioMaxima (WSE:BMX)

Sep 07
Returns On Capital Are Showing Encouraging Signs At BioMaxima (WSE:BMX)

BioMaxima (WSE:BMX) Seems To Use Debt Quite Sensibly

Mar 07
BioMaxima (WSE:BMX) Seems To Use Debt Quite Sensibly

We Think BioMaxima (WSE:BMX) Might Have The DNA Of A Multi-Bagger

Feb 02
We Think BioMaxima (WSE:BMX) Might Have The DNA Of A Multi-Bagger

BioMaxima (WSE:BMX) Knows How To Allocate Capital Effectively

Sep 06
BioMaxima (WSE:BMX) Knows How To Allocate Capital Effectively

We Think BioMaxima (WSE:BMX) Can Stay On Top Of Its Debt

Jun 04
We Think BioMaxima (WSE:BMX) Can Stay On Top Of Its Debt

Does BioMaxima (WSE:BMX) Have A Healthy Balance Sheet?

Feb 18
Does BioMaxima (WSE:BMX) Have A Healthy Balance Sheet?

Are BioMaxima's (WSE:BMX) Statutory Earnings A Good Guide To Its Underlying Profitability?

Jan 14
Are BioMaxima's (WSE:BMX) Statutory Earnings A Good Guide To Its Underlying Profitability?

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak BioMaxima yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

WSE:BMX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (PLN Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
6/30/2024490-55N/A
3/31/2024470-115N/A
12/31/2023471-162N/A
9/30/2023471-181N/A
6/30/2023482-21-3N/A
3/31/2023615-65N/A
12/31/2022144292737N/A
9/30/2022154312630N/A
6/30/2022155312932N/A
3/31/2022146281923N/A
12/31/20217910-50N/A
9/30/2021791238N/A
6/30/20217912711N/A
3/31/2021811458N/A
12/31/202061824N/A
9/30/202046535N/A
6/30/202039301N/A
3/31/202030145N/A
12/31/201931035N/A
9/30/201931-1-3-1N/A
6/30/201931-2-9-1N/A
3/31/201932-1-143N/A
12/31/2018320-152N/A
9/30/2018320-107N/A
6/30/2018331-57N/A
3/31/2018331N/A2N/A
12/31/2017331N/A2N/A
9/30/2017361N/A1N/A
6/30/2017331N/A1N/A
3/31/2017301N/A1N/A
12/31/2016291N/A2N/A
9/30/2016241N/A2N/A
6/30/2016241N/A2N/A
3/31/2016241N/A3N/A
12/31/2015231N/A2N/A
9/30/2015221N/A1N/A
6/30/2015221N/A0N/A
3/31/2015211N/A0N/A
12/31/2014220N/A1N/A
9/30/2014241N/A1N/A
6/30/2014241N/A1N/A
3/31/2014231N/A2N/A
12/31/2013221N/A1N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: Insufficient data to determine if BMX's forecast earnings growth is above the savings rate (3.9%).

Kazançlar ve Piyasa: Insufficient data to determine if BMX's earnings are forecast to grow faster than the Polish market

Yüksek Büyüme Kazançları: Insufficient data to determine if BMX's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: Insufficient data to determine if BMX's revenue is forecast to grow faster than the Polish market.

Yüksek Büyüme Geliri: Insufficient data to determine if BMX's revenue is forecast to grow faster than 20% per year.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if BMX's Return on Equity is forecast to be high in 3 years time


Büyüyen şirketleri keşfedin